Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: Circ-SMARCA5 suppresses progression of multiple myeloma by targeting miR-767-5p

Fig. 3

a: Circ-SMARCA5 relative expression at 24 h after transfection. Circ-SMARCA5 expression was increased in SMARCA5 (+) group compared to Control (+) group but decreased in SMARCA5 (−) group compared with Control (−) group. Comparison of Circ-SMARCA5 expression between two groups was performed by t test. ***P < 0.001. b-g: The effects of Circ-SMARCA5 on proliferation and apoptosis of RPMI8226 cells. Cell proliferation was reduced in SMARCA5 (+) group compared with Control (+) group but promoted in SMARCA5 (−) group compared with Control (−) group (b). Cell apoptosis rate was increased in SMARCA5 (+) group compared with Control (+) group but decreased in SMARCA5 (−) group compared with Control (−) group (c, g). The expression of cell apoptotic marker Cleaved Caspase 3 was elevated in SMARCA5 (+) group compared with Control (+) group but lowered in SMARCA5 (−) group compared with Control (−) group, and for Bcl-2, its expression was reduced in SMARCA5 (+) group compared with Control (+) group but raised in SMARCA5 (−) group compared with Control (−) group (d, e, f). Comparisons of cell proliferation ability and apoptosis rate were by t test, and P < 0.05 was considered significant. **P < 0.01. Round dot represented Control (+) group, square represented SMARCA5 (+) group, regular triangle represented Control (−) group, inverted triangle represented SMARCA5 (−) group. Circ-SMARCA5, Circular RNA SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily A member 5; Control (+), blank overexpression; SMARCA5 (+), Circ-SMARCA5 overexpression; Control (−), blank shRNA; SMARCA5 (−), Circ-SMARCA5 shRNA

Back to article page